MNTA Momenta Pharmaceuticals, Inc

USD 1,969.20 26.40 (+1.36%)
Icon

Momenta Pharmaceuticals, Inc Stock Analysis and Price Target COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

N/A

Average User
Rating

N/A

Average Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis

USD 0.00

0.00 (0.00)%

USD 6.24B

N/A

N/A

N/A

Icon

MNTA

Momenta Pharmaceuticals, Inc (USD)
COMMON STOCK | NSD
USD 1,969.20
26.40 (+1.36%)

N/A

Average User
Rating

N/A

Average Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis

USD 6.24B

N/A

USD 0.00

Momenta Pharmaceuticals, Inc Stock Forecast

N/A

Based on the Momenta Pharmaceuticals, Inc stock forecasts from 0 analysts, the average analyst target price for Momenta Pharmaceuticals, Inc is not available over the next 12 months. Momenta Pharmaceuticals, Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Momenta Pharmaceuticals, Inc is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Momenta Pharmaceuticals, Inc’s stock price was USD 0.00. Momenta Pharmaceuticals, Inc’s stock price has changed by 0% over the past week, 0% over the past month and 0% over the last year.

No recent analyst target price found for Momenta Pharmaceuticals, Inc
No recent average analyst rating found for Momenta Pharmaceuticals, Inc

Company Overview

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc recept...Read More

301 Binney Street, Cambridge, MA, United States, 02142

118

December

USD

USA

Adjusted Closing Price

Loading...

Technical Indicators

  • 1.79

  • N/A

  • 0.79

  • N/A

  • 5,413,387

  • USD 37.73

  • 4,400,542

  • USD 52.38

  • 0.98%

  • 7.57%

  • 103.48%

  • N/A

Unadjusted Closing Price

Loading...

Assets

Top Holdings

Top Sectors

Top Regions

Share Volume

Loading...

Relative Performance

Security Capital Gain Dividend Return Total Return
Loading...

Stocks Similar To Momenta Pharmaceuticals, Inc (Sector: Drug Manufacturers-Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PPD
PPD Inc 0.00 (0.00%) USD16.61B 47.04 21.58
VTRS
Viatris Inc +0.10 (+0.82%) USD14.42B 18.02 6.97
NBIX
Neurocrine Biosciences Inc -0.71 (-0.64%) USD10.41B 180.48 98.51
MYL
Mylan N.V 0.00 (0.00%) USD8.59B 30.73 11.86
APHA
Tilray, Inc 0.00 (0.00%) USD6.86B 60.60 454.68
ALKS
Alkermes Plc +0.05 (+0.17%) USD4.73B N/A -72.85
ITCI
Intracellular Th -0.10 (-0.21%) USD4.45B N/A -14.58
LNTH
Lantheus Holdings Inc +1.14 (+1.98%) USD3.86B 36.91 16.96
EVO
Evotec SE ADR +0.10 (+1.03%) USD3.66B 508.00 -19.09
HCM
HUTCHMED DRC +0.73 (+4.05%) USD3.64B 17.69 -6.38

ETFs Containing MNTA

Symbol Name Weight Mer Price(Change) Market Cap
no data

Frequently Asked Questions About MNTA Stock

Stock Target Advisor's fundamental analysis for Momenta Pharmaceuticals, Inc's stock is Very Bearish.

Unfortunately we do not have enough data on MNTA's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on MNTA's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on MNTA's stock to indicate if its overvalued.

Unfortunately we do not currently have any pricing data for MNTA's stock.

The most recent market capitalization for MNTA is USD 6.24B.

Unfortunately we do not have enough analyst data on MNTA's stock to indicate whether its price will go up or not.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...